Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Korean Circ J. 2010 Aug;40(8):370-6. doi: 10.4070/kcj.2010.40.8.370. Epub 2010 Aug 31.
Pentraxin 3 (PTX3) was shown to be elevated in the acute phase of acute myocardial infarction (AMI) and to have prognostic significance in AMI patients. The aim of this study was to estimate whether the value of PTX3 could be used as a prognostic biomarker, with the global registry of acute coronary events (GRACE) risk assessment tool, in patients with acute coronary syndrome (ACS).
Between July 2007 and June 2008, 137 patient subjects (mean age : 61±12 years, M : F=108 : 29) with ACS who underwent coronary intervention, but did not have a prior percutaneous coronary intervention (PCI) and/or follow-up coronary angiogram, were enrolled. We estimated the all-cause mortality or death/MI, in-hospital and to 6 months, using the GRACE risk scores and compared these estimates with serum PTX3 concentrations.
The serum PTX3 concentration showed a significant increase in ST segment elevation myocardial infarction (STEMI) greater than the unstable angina pectoris (UAP) group (2.4±2.1 ng/mL vs. 1.3±0.9 ng/mL, p= 0.017, respectively), but did not show a significant difference between non-ST segment elevation myocardial infarction (NSTEMI) and the UAP group (1.9±1.4 ng/mL vs. 1.3±0.9 ng/mL, p=0.083, respectively). The serum PTX3 concentration was closely related to death/MI in-hospital (r=0.242, p=0.015) and death/MI to 6 months (r=0.224, p=0.023), respectively. The serum PTX3 concentration was not related to all-cause mortality in-hospital (r=0.112, p=0.269) and to 6 months (r=0.132, p=0.191), respectively. Among the parameters determining the GRACE risk scores, the degree of Killip class in congestive heart failure (CHF) was independently associated with the supramedian PTX3 concentration [odds ratio: 2.229 (95% confidence interval: 1.038-4.787), p=0.040].
The serum PTX3 level provides important information for the risk stratification of CHF among the parameters determining the GRACE risk scores in subjects with ACS.
Pentraxin 3（PTX3）在急性心肌梗死（AMI）的急性期升高，并在 AMI 患者中有预后意义。本研究的目的是评估在急性冠脉综合征（ACS）患者中，PTX3 的价值是否可以作为一种预后生物标志物，与全球急性冠脉事件注册（GRACE）风险评估工具相结合。
2007 年 7 月至 2008 年 6 月，共纳入 137 名接受冠状动脉介入治疗但无既往经皮冠状动脉介入治疗（PCI）和/或随访冠状动脉造影的 ACS 患者（平均年龄：61±12 岁，男性：女性=108：29）。我们使用 GRACE 风险评分估计全因死亡率或死亡/心肌梗死、住院期间和 6 个月时的死亡率，并将这些估计值与血清 PTX3 浓度进行比较。
ST 段抬高型心肌梗死（STEMI）组的血清 PTX3 浓度显著高于不稳定型心绞痛（UAP）组（2.4±2.1 ng/mL 比 1.3±0.9 ng/mL，p=0.017），而非 ST 段抬高型心肌梗死（NSTEMI）组与 UAP 组之间无显著差异（1.9±1.4 ng/mL 比 1.3±0.9 ng/mL，p=0.083）。血清 PTX3 浓度与住院期间死亡/心肌梗死密切相关（r=0.242，p=0.015），与 6 个月时死亡/心肌梗死相关（r=0.224，p=0.023）。血清 PTX3 浓度与住院期间全因死亡率（r=0.112，p=0.269）和 6 个月时全因死亡率（r=0.132，p=0.191）均无相关性。在确定 GRACE 风险评分的参数中，充血性心力衰竭（CHF）的 Killip 分级程度与高于中位数的 PTX3 浓度独立相关[比值比：2.229（95%置信区间：1.038-4.787），p=0.040]。
在 ACS 患者中，血清 PTX3 水平为确定 GRACE 风险评分的参数提供了 CHF 风险分层的重要信息。
Zotero 插件
